Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.22.2.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Jun. 30, 2022
Current assets:    
Cash and cash equivalents $ 165,257 $ 172,567
Short-term available-for-sale investments 37,818 74,462
Accounts receivable, less allowance for doubtful accounts of $2,496 and $2,568, respectively 174,174 194,548
Inventories 150,009 141,123
Other current assets 24,773 22,856
Total current assets 552,031 605,556
Property and equipment, net 224,098 223,242
Right of use asset 69,745 65,556
Goodwill 865,418 822,101
Intangible assets, net 585,534 531,522
Other assets 53,895 46,828
Total assets 2,350,721 2,294,805
Current liabilities:    
Trade accounts payable 30,475 33,865
Salaries, wages and related accruals 32,557 61,953
Accrued expenses 13,790 17,886
Contract liabilities 22,059 23,406
Income taxes payable 17,270 13,237
Operating lease liabilities - current 12,115 11,928
Contingent consideration payable 7,400  
Current portion of long-term debt obligations   12,500
Other current liabilities 1,963 1,243
Total current liabilities 137,629 176,018
Deferred income taxes 112,920 98,994
Long-term debt obligations 264,661 243,410
Long-term contingent consideration payable 8,100 5,000
Operating lease liabilities 64,756 58,133
Other long-term liabilities 11,501 12,239
Bio-Techne's Shareholders' equity:    
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding 0 0
Common stock, par value $.01 per share; authorized 100,000,000; issued and outstanding 39,232,094 and 39,160,000, respectively 392 392
Additional paid-in capital 680,057 653,657
Retained earnings 1,162,515 1,122,921
Accumulated other comprehensive loss (91,810) (75,200)
Total Bio-Techne's shareholders' equity 1,751,154 1,701,770
Noncontrolling interest   (759)
Total shareholders' equity 1,751,154 1,701,011
Total liabilities and shareholders' equity $ 2,350,721 $ 2,294,805